Stray Dog

Hims Stock: One Big Mistake, One Bigger Bet. Is It Worth Owning?

Key takeaways

  1. Intake forms and blood tests build each user's record: across 2.5 million subscribers, a data loop Hims argues newcomers cannot easily copy.
  2. Hims rightly saw weight loss as key, but selling copies of Novo Nordisk's drugs ended a partnership and cost the stock over 30% in a day.
  3. Rival Ro partnered with Novo and Eli Lilly from the start; Hims now sells authentic Wegovy, but rebuilding trust takes time.
  4. It is spending big: about $400 million raised through convertible notes, and a $1.15 billion deal for Eucalyptus, an Australian digital health company.
  5. The case is not broken, but it is under pressure: watch revenue per subscriber, which dipped from $84 to $80, and whether Wegovy subscribers stay.

Ask a question